Janna Bereuter was the coordinator for the first clinical study of Debacterol® conducted at the University of Minnesota in 1997. Since then she has worked with EPIEN Medical Inc. as a consultant, writing protocols, and staying in touch with the dental community.

Prior to becoming Vice President of Clinical Research for EPIEN Medical Inc., Ms. Bereuter consulted on several research projects for a wide variety of dental companies including Implant Innovations, Inc.; Block Drug Company, Inc.; and Stryker Biotech LLC.

Ms. Bereuter was the first Clinic Coordinator at the Minnesota Clinical Research Center at the University of Minnesota (1993 to 1999). Since then she has worked extensively in clinical research in the private sector. Working at Medafor, Inc. as Clinical Director, Ms. Bereuter wrote a three-arm protocol and monitored ten clinical sites resulting in the successful completion of the PMA for a plant-based hemostatic device (Arista^TM). As co-founder and Director of Clinical and Regulatory Affairs for Chitogen, Inc., Ms. Bereuter obtained 510 (k) FDA clearance for an animal- based hemostatic device (SoftSeal®-STF). As an Applications Specialist and Project Manager for Medistim, Ms. Bereuter wrote the protocol and contracts, selected the research sites, and managed the REQUEST study in blood flow dynamics during cardiac surgery. This was the first multi-center study documenting surgical adjustments resulting from the intra-operative use of Transit Time Flow Measurement (TTFM) and High-Frequency Ultrasound Imaging (HFUS). The REQUEST study was completed in six countries in 2016 and continues to be cited in new cardiac publications as well as continuing to be the source of new publications written by the original investigators.

Ms. Bereuter received her bachelor’s degree in Biology and Education from Concordia College in Moorhead, Minnesota. She continued her education with post-graduate courses at the University of Minnesota, School of Dentistry.